Telomere biology disorders (TBDs) are a group of rare diseases caused by mutations that impair telomere maintenance. Mutations that cause reduced levels of TERC/hTR, the telomerase RNA component, are found in most TBD patients and include loss-of-function mutations in hTR itself, in hTR-binding proteins [NOP10, NHP2, NAF1, ZCCHC8, and dyskerin (DKC1)], and in proteins required for hTR processing (PARN). These patients show diverse clinical presentations that most commonly include bone marrow failure (BMF)/aplastic anemia (AA), pulmonary fibrosis, and liver cirrhosis. There are no curative therapies for TBD patients. An understanding of hTR biogenesis, maturation, and degradation has identified pathways and pharmacological agents targeting the poly(A) polymerase PAPD5, which adds 3′-oligoadenosine tails to hTR to promote hTR degradation, and TGS1, which modifies the 5′-cap structure of hTR to enhance degradation, as possible therapeutic approaches. Critical next steps will be clinical trials to establish the effectiveness and potential side effects of these compounds in TBD patients.

Telomeres and telomerase are essential for tissue homeostasis

Telomeres are repetitive DNA sequences that cap chromosomal ends and are composed of an array of double-stranded TTAGGG repeats followed by a single-stranded 3′ overhang of 40–500 nt in length [1–3]. Telomeres are protected by shelterin, a six-protein complex that prevents telomeres from being recognized as DNA double-stranded breaks, through a conformational change in telomeric DNA where the 3′ overhang folds back to form a telomere (t)-loop structure (Figure 1A).

Although this complex biochemical structure is essential to prevent erroneous activation of DNA damage responses at chromosomal ends [4], it also makes the replication of DNA ends a challenging process (recently reviewed [5]). In fact, telomeres shorten by up to 200 bp at each cell division, due to the inability of replicative DNA polymerases to fully extend the lagging strand of DNA replication at telomeres [6]. Telomeres therefore become progressively shorter over time, and, once a critical length is reached, cellular senescence is triggered [7,8].

In cells with high proliferative potential, such as germline and somatic stem cells, this DNA 'end-replication' problem is solved by telomerase (see Glossary), a ribonucleoprotein complex composed at its core by TERT (the telomerase reverse transcriptase component) and hTR (the telomerase RNA component) that serves as the template for the addition of telomeric repeats to the ends of linear chromosomes [6,9]. Although these core components are sufficient for telomerase activity in vitro, the assembled telomerase complex in vivo is far larger, and includes the RNA-binding proteins DKC1, NOP10, NHP2, GAR1, and TCAB1 (Figure 1B). These components are assembled through direct or indirect binding to hTR, thereby increasing the stability of the hTR RNA and increasing telomerase activity in vivo. Several other proteins interact transiently with telomerase, including those that modify hTR (PARN) and those that regulate hTR metabolism (PAPD5, TGS1).

Telomeres and telomerase are essential for tissue homeostasis, telomere maintenance, and include loss-of-function mutations in hTR itself, in hTR-binding proteins, and in proteins required for hTR processing. Critical next steps will be clinical trials to establish the effectiveness and potential side effects of these compounds in TBD patients.

Telomere biology disorders (TBDs) are a group of rare diseases caused by mutations that impair telomere maintenance. Mutations that cause reduced levels of TERC/hTR, the telomerase RNA component, are found in most TBD patients and include loss-of-function mutations in hTR itself, in hTR-binding proteins [NOP10, NHP2, NAF1, ZCCHC8, and dyskerin (DKC1)], and in proteins required for hTR processing (PARN). These patients show diverse clinical presentations that most commonly include bone marrow failure (BMF)/aplastic anemia (AA), pulmonary fibrosis, and liver cirrhosis. There are no curative therapies for TBD patients. An understanding of hTR biogenesis, maturation, and degradation has identified pathways and pharmacological agents targeting the poly(A) polymerase PAPD5, which adds 3′-oligoadenosine tails to hTR to promote hTR degradation, and TGS1, which modifies the 5′-cap structure of hTR to enhance degradation, as possible therapeutic approaches. Critical next steps will be clinical trials to establish the effectiveness and potential side effects of these compounds in TBD patients.

Telomeres and telomerase are essential for tissue homeostasis, telomere maintenance, and include loss-of-function mutations in hTR itself, in hTR-binding proteins, and in proteins required for hTR processing. Critical next steps will be clinical trials to establish the effectiveness and potential side effects of these compounds in TBD patients.

Highlights

Mutations in genes associated with telomere maintenance occur in telomere biology disorders (TBDs). These poorly treated disorders are characterized by multisystemic phenotypes including bone marrow failure/aplastic anemia, pulmonary fibrosis, liver cirrhosis, and increased cancer incidence.

Mutations that cause reduced levels of TERC/hTR, the telomerase RNA component, are found in most TBD patients and include loss-of-function mutations in hTR itself, in several hTR-binding proteins, and in proteins required for post-transcriptional hTR processing. These mutations culminate in increased hTR 3′-end oligo-adenylation by the noncanonical poly(A) polymerase PAPD5, which triggers exonucleolytic decay of the telomerase RNA component.

Recent evidence shows that genetic or chemical inhibition of PAPD5 can rescue telomere homeostasis and cellular functionality in both murine and human models of TBDs, indicating this could serve as a possible therapeutic approach for several TBDs.

1Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA
2Center for Genome Integrity, Washington University in St. Louis, St. Louis, MO, USA
3Center of Regenerative Medicine, Washington University in St. Louis, St. Louis, MO, USA
4Centre for Genomics and Child Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
5Department of Biochemistry and Biopharmaceuticals Institute, University of Colorado Boulder, Boulder, CO, USA
6Department of Biochemistry, University of Colorado Boulder, Boulder, CO, USA

882 Trends in Molecular Medicine, October 2022, Vol. 28, No. 10 https://doi.org/10.1016/j.molmed.2022.08.001 © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
telomerase and are necessary for its assembly, trafficking, and binding to telomeres (a review on telomerase assembly and function can be found in [10]). In metazoans, telomerase expression is primarily regulated by the expression of TERT, which in humans is mostly restricted to germline and somatic stem and progenitor cells [11]. As these cells are responsible for tissue repopulation and long-term viability [12], it is not surprising that telomerase activity is essential for continued
stem cell function and tissue homeostasis [13,14]. While the regulation of telomerase activity remains a complex issue, recent advances in our understanding of TERT expression [15], hTR stability [10], and the recruitment of telomerase to telomeres [3] could finally allow targeted modulation of telomere length in different cell types. Such knowledge could have broad implications for the regulation of physiological aging, or, as we will discuss in more detail here, in the clinical management of disorders where telomeres are exceptionally short.

**Telomere biology disorders**

Given the importance of telomerase in somatic stem cells, germline mutations that impair telomere structure, replication, and telomerase function are linked to severe, widespread phenotypes and a shortened lifespan in patients [16–18]. First genetically characterized in 1998 in pediatric dyskeratosis congenita (DC) patients suffering from BMF [19], mutations that cause exacerbated telomere shortening are currently identified in different age groups and in patients suffering from different conditions. Collectively, these conditions are referred to as telomeropathies or TBDs [20].

TBDs commonly involve multiple organ systems and are associated with the premature loss of tissue-repopulating cells, leading to a reduction in the regenerative capacity of the organs affected [17]. This loss of tissue homeostasis is directly linked to activation of DNA damage responses from dysfunctional telomeres [21–26], and in vitro and in vivo experiments show that reactivation of telomerase activity efficiently restores tissue functionality [23,27]. In some families affected with TBDs, disease manifestations occur at an earlier age and with more severe phenotypes in successive generations, a phenomenon referred to as genetic anticipation [28]. Although a common phenotype associated with TBDs is BMF/AA, multisystemic defects are also usually found in patients. In this regard, DC is a pediatric BMF syndrome that is associated with a ‘triad’ of nail dysplasia, oral leukoplaikia, and lacy reticular pigmentaion [29].

Clinical presentations in DC can vary depending on age of diagnosis, mode of inheritance (autosomal dominant, AD; autosomal recessive, AR; X-linked; or de novo), and the specific genes mutated [30], and associated features typically include premature greying of hair, pulmonary fibrosis, emphysema, and liver fibrosis [29]. More severe pediatric manifestations of telomere shortening can be found in Hoyeraal–Hreidarsson syndrome (HHS), where patients also present with cerebellar hypoplasia, in Revesz syndrome, where patients typically present with associated retinal pathology, and in Coats plus, where patients show an array of neurological abnormalities that lead to slow growth, seizures, movement disorders, and decreasing intellectual function [17]. In cases of adult onset, the most common phenotype of TBDs is pulmonary fibrosis, but these can also present with AA and liver disease [31]. Patients with DC are also at an increased risk of developing cancer compared with the general population. The types of malignancies most commonly associated with TBDs are head and neck squamous cell carcinoma, myelodysplastic syndromes, and acute myeloid leukemia [32,33]. Several other severe complications can be found in these patients, ranging from gastrointestinal to immunologic abnormalities [33].

While enormous progress has been made into the genetics and the characterization of TBDs, these syndromes remain without a general cure [34]. Management of hematopoietic failure in TBDs is challenging. The use of erythropoietin and granulocyte colony-stimulating factor (GCSF) does not produce durable improvements in red cell and neutrophil counts [35]. Similarly, immunosuppressive therapy with cyclosporin and anti-thymocyte globulin does not yield a good response in DC patients [36], and is not a recommended approach. While eltrombopag has recently been given approval for therapy in patients with severe AA, the use of this small molecule is not recommended for patients with DC as case reports show no response to
treatment [37]. Androgen therapy leads to multiple lineage rescue in a variety of BMF patients, and it has been described to elicit a good response in many DC patients. Danazol is now the preferred androgen in the treatment of DC [38]. It can produce very good clinical responses in ~70% of patients. The precise mechanisms of danazol action and its effects on telomere elongation remain unclear, but may be related to increased expression of TERT [33]. However, in a subgroup of patients the drug has to be discontinued because of toxicity [39].

Hematopoietic stem cell transplantation (HSCT) represents the only curative therapy for BMF/AA in TBDs, but the outcome of this procedure remains highly variable [40]. High morbidity and mortality were observed with conventional myeloablative HSCT approaches, and the use of reduced-intensity fludarabine-based conditioning regimens has led to significant progress in HSCT in DC patients. A comprehensive description of HSCT in TBDs is outside the scope of this article and can be found in [35]. Despite progress with current HSCT approaches, therapy for the extra-hematopoietic defects remains a challenge. A fundamental limitation is that TBDs often present as multisystem syndromes and HSCT does not correct the extra-hematopoietic abnormalities. Indeed, HSCT is usually only recommended in TBD cases with severe and progressive BMF who have minimal comorbidities [33]. Therefore, alternatives to HSCT are desirable; ideally, therapies capable of targeting the disease specific defect need to be developed and brought to the clinic.

Telomerase RNA component: a central element in telomere biology disorders

Current understanding of the biogenesis and regulation of the telomerase complex, including the telomerase RNA component, identifies multiple perturbations that can cause TBDs and points to possible targets for therapeutic intervention. Mutations in several genes that regulate different aspects of telomere homeostasis are found in TBD patients [16]. These include mutations in shelterin, mutations in proteins involved in telomere replication, and mutations in the telomerase complex itself. Table 1 presents a summary of mutations in TBDs, and a comprehensive analysis of how these different mutations lead to patient phenotypes can be found in [20]. We focus here on mutations that impair telomerase function through a reduction in mature hTR levels caused by

| Gene/product | Biological role | Associated diseases* |
|--------------|----------------|----------------------|
| ACD/TPP1     | Component of the shelterin complex | AA, DC |
| CTC1/CTC1    | Component of the CST complex | DC, CP |
| DKC1/Dyskeratint | hTR stability; component of telomerase | AA, DC, PF |
| NAF1/NAF1   | Component of the dyskerin complex | PF |
| NOLA2/NHP2  | Component of the dyskerin complex | DC |
| NOLA3/NOP10t | Component of the dyskerin complex | DC |
| PARNPARN    | hTR processing | DC, PF |
| RTEL1/RTEL1 | Telomere replication | DC, PF |
| RPA1/RPA1    | DNA replication/repair | DC, PF |
| TERCT/TR t   | Component of telomerase | AA, DC, PF |
| TERT/TERT    | Component of telomerase | AA, DC |
| TINF2/TIN2   | Component of the shelterin complex | AA, DC |
| WRAP53/TCAB1 | Component of telomerase | DC |
| ZCCHC8/ZCCHC8 | hTR processing | PF |

*Abbreviations: AA, aplastic anemia; CP, Coats plus; DC, dyskeratosis congenita; PF, pulmonary fibrosis.

tMutations that impair hTR levels/function.
unbalanced maturation and degradation of these RNA molecules in vivo. These are the types of mutations where targeted pharmacological intervention now appears to be possible.

hTR is a small Cajal body RNA (scRNA) and small nucleolar RNA (snoRNA) that contains an H/ACA domain [41]. This H/ACA domain guides the pseudouridylation of both ribosomal (rRNA) and small nuclear (snRNA) RNAs by the dyskerin complex (composed of DKC1, NOP10, NHP2, and NAF1) [42,43]. The interaction of hTR with the dyskerin complex is crucial for hTR stability and processing, and is thus essential for telomerase function [44,45]. Mutations in either hTR or members of the dyskerin complex that disrupt the hTR–dyskerin interaction are found in TBD patients (Table 1), and cause low telomerase activity and progressive telomere shortening in TERT-positive cells [20]. A key point is that these mutations destabilize hTR and that this is the pathogenic mechanism in patients harboring such mutations. This is demonstrated by the fact that overexpression of hTR in cells harboring mutations that prevent the stable assembly of hTR with the dyskerin pseudouridylation complex rescues telomerase activity, promotes telomere elongation, and improves cellular viability [46,47]. Mutations in other sites of hTR have also been found in TBD patients, including mutations in the pseudoknot domain (which contains the template region) and mutations in the CR4/5 domain which also disrupt the catalytic function of telomerase.

An understanding of hTR transcription, processing, and degradation has been crucial for the development of possible therapeutic interventions (Figure 2). hTR is transcribed by RNA polymerase II from its own promoter [48]. Although most mature hTR transcripts end at position 451 [49], hTR is initially transcribed as longer precursors (461–1500 nt in length) which are post-transcriptionally processed into the mature form by 3′ to 5′ exonuclease

Figure 2. Telomerase RNA component (hTR) biogenesis and processing. Nascent hTR contains 3′ extensions (depicted in blue) that are polyadenylated by PAPD5, leading to their exonucleolytic decay by the exosome. Alternatively, 3′ exonucleases can trim these 3′ extensions, leading to the formation of mature hTR molecules. PAPD5 can also adenylate fully trimmed hTR molecules to promote their 3′ to 5′ degradation, which is increased in patient cells lacking dyskerin (DKC). Binding of hTR to the dyskerin complex (through its H/ACA domain) increases hTR stability. Binding to TCAB1 (through its CAB box domain) is necessary for telomerase trafficking to Cajal bodies (not shown), which aids in the formation of functional telomerase complexes.
trimming, as well as by oligo-adenylation of the 3’ end of nascent transcripts by the noncanonical poly(A) polymerase PAPD5 [50–52]. PAPD5-mediated polyadenylation of hTR 3’ ends can also target hTR for degradation by the RNA exosome complex [50,51]. In turn, the recruitment of the RNA exosome complex is performed by the nuclear exosome targeting complex (NEXT) and the cap-binding complex (CBC) [53]. Working in opposition to PAPD5, poly(A)-specific ribonuclease (PARN) deadenylates hTR transcripts, preventing their degradation and leading to accumulation of mature, functional hTR transcripts [49–51].

This balance between hTR maturation and degradation is disturbed in TBDs patients harboring loss-of-function mutations in PARN. These patients show low levels of mature hTR, resulting in reduced telomerase activity and telomere shortening [51,54–56]. Similarly, patients harboring mutations in the NEXT component ZCCHC8 were recently identified [57], where levels between immature and mature forms of hTR were also imbalanced. Mutations in ZCCHC8 cause significantly reduced levels of mature forms of hTR, leading to reduced telomerase activity and exacerbated telomere shortening [57].

Collectively, it becomes clear that correct hTR processing and stability is essential for telomerase function, and is impaired in a significant number of patients suffering from TBDs. A common consequence of defective RNA processing, or ribonucleoprotein (RNP) assembly, is degradation of the telomerase RNA, leading to TBDs. Thus, strategies to restore mature hTR levels represent an attractive target to restore telomere instability in these patients, which could lead to significant clinical improvement.

Restoring hTR levels through PAPD5 inhibition as a novel approach against TBDs

The role of PAPD5 in adenylating hTR to promote its degradation by the exosome suggests that inhibition of PAPD5 might be an approach to restoring telomerase activity in TBDs where hTR levels are reduced. Importantly, genetic inhibition of PAPD5 by short hairpin (sh)RNAs in human cells harboring different mutations that affect hTR biogenesis (i.e., in DKC1 and PARN) leads to a reduction of 3’ extended hTR molecules, as well as to an increase in the number of deadenylated, functional hTR molecules [49,50,58]. Moreover, inhibition of PAPD5 is followed by an increase in telomerase assembly and recruitment, as well as an increase in telomerase activity, in cells harboring pathogenic mutations that impair hTR levels [50,58]. This causes significant elongation of telomeres in these cells and a reduction in the activation of DNA damage responses (DDR), opening the possibility that inhibition of PAPD5 could mitigate the molecular trigger leading to tissue failure in TBDs.

As a major phenotype associated with hTR deficiency is impaired hematopoietic development that culminates in BMF, experiments were performed to determine whether PAPD5 inhibition could alleviate the hematopoietic deficit caused by telomerase dysfunction. Experiments with DKC1 mutant human embryonic stem cells (hESCs) determined that silencing of PAPD5 in these cells restores their in vitro hematopoietic differentiation capacity, through direct regulation of the 3’-end maturation of hTR [59]. Silencing of PAPD5 restored trilineage hematopoietic differentiation and increased myeloid, erythroid, and T cell cellularity. Of note, unlike the silencing of the exosome component 3 (EXOSC3), silencing of PAPD5 was not toxic to human hematopoietic cells [59], suggesting that pharmacological inhibition of PAPD5 could be a possible therapy for TBDs caused by reduced hTR levels. However, it remains to be determined whether the broad and persistent inhibition of PAPD5 could be toxic to different cell types, and, if so, to what extent this could impair tissue functionality in clinical settings.
PAPD5 is a good target for drug discovery. Since PAPD5 and its paralog poly(A) polymerase PAPD7 are required for hepatitis B virus (HBV) infections [60], some biotech companies have developed inhibitors of PAPD5/7 which have proved effective in restoring hTR levels in relevant TBDs. Treatment with RG7834, a dihydroquinolizinone that acts as a PAPD5 and PAPD7 inhibitor [61], culminated in a reduction of 3′-end oligoadenylation in hTR molecules in PARN and DKC1 mutant cells [62]. This was followed by increased mature levels of hTR in these cells, increased telomerase assembly, and higher levels of telomerase activity and telomere lengthening. Moreover, treatment with low concentrations of RG7834 rescued hematopoietic development of DKC1 mutant cells, leading to higher formation of erythroid and myeloid colonies [62]. These improvements were achieved with a modest increase in hTR levels (approximately twofold), suggesting a reasonable therapeutic window. In addition, pharmacological inhibition of PAPD5 (achieved with either RG8734 or BCH001) significantly reduced 3′-end oligoadenylation in PARN-mutant primary hematopoietic stem and progenitor cells (HSPCs), without detectable toxicity [63]. Finally, RG7834 rescued hTR 3′-end maturation over time in xenotransplantation experiments of PARN-mutant human CD34+ cells into immunocompromised mice [63]. In these experiments, RG7834 was supplied orally over months through drinking water, and no adverse effects were reported [63].

These recent observations indicate that pharmacological inhibition of PAPD5 represents an exciting new therapeutic approach in TBDs, which currently remain without a cure. As TBDs are characterized by multisystemic defects, it will be important to determine the extent to which PAPD5 inhibition can also rescue functionality in other tissues that are frequently impaired in patients (i.e., it remains to be determined to what extent restoration of hTR levels is effective in slowly proliferative or postmitotic tissues). Similarly, deeper studies are necessary to identify other possible targets of PAPD5/7 in different cell types, and how these could influence tissue functionality or treatment. These are necessary studies that will also help to determine the safety and breadth of this approach before future clinical trials.

**TGS1 as alternative target for restoring hTR levels**

A second approach to restoring hTR levels in relevant TBDs would be to target the enzyme trimethylguanosine synthase 1 which modifies the hTR RNA during biogenesis. Specifically, during the early stages of transcription, hTR molecules acquire a 5′-end m7G trimethylguanosine (TMG) cap, which is then further methylated to a N2,2,7-trimethylguanosine (TMG) cap by trimethylguanosine synthase 1 (TGS1) [64]. The formation of the TMG cap controls telomerase trafficking and accumulation, and inhibition of TGS1 increases hTR levels, possibly by restricting its localization to Cajal bodies and thereby preventing its degradation in the cytoplasm [10]. Ablation of TGS1 results in increased telomerase activity and telomere extension [65]. Interestingly, inhibition of TGS1 has also been shown to trigger different molecular markers of alternative lengthening of telomeres (ALT) in human cells, pointing to a possible dual role of TGS1 in telomere maintenance [66]. In fact, treatment of different human cell types with sinefungin, a compound that inhibits the methyltransferase activity of TGS1, leads to telomerase elongation in wild type and PARN-mutant settings [67]. Therefore, the chemical inhibition of TGS1 could represent another route for rescue of telomerase activity in a subset of TBD patients where hTR levels are disrupted, although how well inhibition of TGS1 can rescue the hematopoietic deficits remains to be determined. One possibility is that TGS1 inhibition could be combined with concomitant inhibition of PAPD5 for more robust restoration of telomerase RNA levels. Such strategies should be further tested in different in vitro and in vivo models.
Concluding remarks
The progressive shortening of telomere length observed in the human population is intrinsically associated with physiological aging, and regulates multiple biological traits, including life-expectancy [68]. Germline mutations in genes involved in telomere elongation, replication, and repair exacerbate these phenotypes and lead to severe tissue failure in patients with TBDs. Although these Mendelian diseases are rare and present with a multitude of different phenotypes, our ability to identify these patients has significantly improved over the past few years. However, treatment options remain unsatisfactory, and novel approaches are needed to improve patients’ quality of life.

A possible therapeutic approach is to modulate the pathways that regulate the levels of hTR in human tissue stem and progenitor cells. Collectively, mutations that impair hTR processing and lead to increased hTR degradation represent the majority of cases identified in patients suffering from TBDs. Critically, our knowledge of the mechanisms that control the biogenesis and degradation of hTR has significantly increased in recent years, allowing targeted modulation of the pathways that regulate hTR levels in tissue progenitor cells.

Pharmaceutical inhibition of PAPD5 seems to be the most promising route to be pursued. Inhibition of PAPD5 restores hTR levels and function, leading to rescue of telomerase activity and improvement in hematopoietic potential. Compounds that specifically inhibit PAPD5/PAPD7 can effectively rescue hematopoietic phenotypes associated with telomere dysfunction in culture and in animal models.

There are several unanswered questions (see Outstanding questions). One critical aspect is the specificity and potential toxicity of PAPD5 inhibitors in the diversity of different cell types in a patient. On the optimistic side, chemical inhibition of PAPD5 leads to only small changes in the transcriptome of hESCs or induced pluripotent stem cells (iPSCs) [62,63], and was relatively non-toxic in mice [63]. However, it remains possible that PAPD5 has important functions in some yet to be identified cell type(s). If there are unanticipated toxicities due to PAPD5 inhibition, one possibility is that patients could be treated in cycles that would allow an increase in telomerase activity and telomere length, followed by an off-treatment period to mitigate possible toxicities.

Taken together, the promising biochemical and cellular data collected so far strongly suggest that regulation of hTR levels by PAPD5 inhibition could prove beneficial for TBD patients. This possibility should be pursued further because it represents an exciting opportunity for transition into the clinic as a possible therapy for some TBDs if future studies demonstrate that they have a favorable efficacy/toxicity profile.

Acknowledgments
During the writing of this perspective the laboratory of L.F.Z.B. was supported by the National Institutes of Health (R01HL137793 and R01CA258386), Department of Defense (DOD) (BM200111), the American Cancer Society, and the Siteman Cancer Center at Washington University in St. Louis. I.D. is funded by Blood Cancer UK and the Medical Research Council. R.P. is funded by the Howard Hughes Medical Institute and the DOD (BM200111).

Declaration of interests
R.P. is a founder and consultant for Faze Medicines. The other authors declare no conflicts of interest.

References
1. Palm, W. and de Lange, T. (2008) How shelterin protects mammalian telomeres. Annu. Rev. Genet. 42, 301–334
2. Chan, S.R. and Blackburn, E.H. (2004) Telomeres and telomerase. Philos. Trans. R. Soc. Lond. B Biol. Sci. 359, 109–121
3. Lim, C.J. and Cech, T.R. (2021) Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization. Nat. Rev. Mol. Cell Biol. 22, 283–298
4. Lazzarini-Dench, E. and Sleik, A. (2018) Stop pulling my strings - what telomeres taught us about the DNA damage response. Nat. Rev. Mol. Cell Biol. 17, 364–378
5. Gloor, G. and Lingner, J. (2021) Challenging endpoints: how telomeres prevent fragility. Bioessays 43, e2100157
6. Schmitz, J.C. and Cech, T.R. (2015) Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev. 29, 1096–1106
7. Nakamura, T.M., et al., Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 566–569
8. Wiley, C.D. and Campisi, J. (2021) The metabolic roots of telomere biology disorders. Exp. Biol. Med. 246, 313–321
9. Schmidt, J.C. and Cech, T.R. (2015) Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev. 29, 1096–1106
10. Bertuch, A.A. (2016) The molecular genetics of the telomere in check. Rev. Mol. Cell Biol. 21, 384–397
11. Li, J.S.Z. and Denchi, E.L. (2018) How stem cells keep telomeres in check. Differentiation 100, 21–25
12. Post, Y. and Clevers, H. (2019) De 890 Trends in Molecular Medicine, October 2022, Vol. 28, No. 10
13. Kirwan, M. and Dokal, I. (2009) Dyskeratosis congenita, stem cells, and telomeres. Biochim. Biophys. Acta 1792, 371–379
14. Heiss, N.S. (2016) Telomeres in aging and disease: lessons from zebra fish. Dis. Model. Mech. 9, 529–541
15. Penev, A. (2016) Telomeres in aging and disease: lessons from zebra fish. Dis. Model. Mech. 9, 529–541
16. Armanios, M. and Blackburn, E.H. (2012) The telomere syndromes. Nat. Rev. Genet. 13, 690–704
17. Savage, S.A. (2011) Beginning at the ends: telomeres and human disease. PLoS Genet. 7, 524
18. Kirwan, M. and Dokal, I. (2009) Dyskeratosis congenita, stem cells and telomeres. Trends in Molecular Medicine. Vol. 28, No. 10
19. Heiss, N.S. et al. (1998) X-linked dyskeratosis congenita is caused by mutations in TERC.
20. Gril, S. and Nandanwar, J. (2021) Molecular mechanisms of telomere biology disorders. J. Biol. Chem. 296, 100004
21. Carneiro, M.C. et al. (2016) Telomeres in aging and disease: lessons from zebra fish. Dis. Model. Mech. 9, 377–383
22. Lee, H.W. et al. (1998) Essential role of mouse telomerase in prostate carcinogenesis. Nat. Rev. Mol. Cell Biol. 23, 384–397
23. Jaskelioff, M. et al. (2011) Telomerase reactivation reverses molecular hallmarks of telomere disease. Nature 474, 399–402
24. Feng, J. et al. (1995) The RNA component of human telomerase. Science 269, 1236–1241
25. Roole, C.M. et al. (2019) Disruption of telomerase RNA maturation kinetics precipitates disease. Mol. Cell 74, 569–574
26. Rakic, P. et al. (2011) Telomerase reactivation reverses tissue degeneration in aged telomere-deficient mice. Nat. Genet. 43, 102–106
27. d’Adda di Fagagna, F. et al. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198
28. Gu, B. et al. (2003) Pathogenic dyskerin mutation impairs proliferation and activates a DNA damage response independent of telomere length in mice. Proc. Natl. Acad. Sci. U. S. A. 105, 10173–10178
29. Kirwan, M. et al. (2011) Dyskeratosis congenita and the DNA damage response. Br. J. Haematol. 153, 634–643
30. Fokin, W.C. et al. (2017) p53 Mediates failure of human definitive hematopoiesis in dyskeratosis congenita. Stem Cell Rep. 9, 409–418
31. Vullumey, T. et al. (2004) Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat. Genet. 36, 447–449
32. Niewiorka, M.R. and Szulwajka, A.S. (2019) An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert. Rev. Hematol. 12, 1052–1052
33. Bercht, A.A. (2016) The molecular genetics of the telomere biology disorders. Rev. Mol. Cell Biol. 15, 590–606
34. Armanios, M. (2012) Telomerase and idiopathic pulmonary fibrosis. Mutat. Res. 730, 52–58
35. Schmitt, J.C. and Armanios, M. (2020) Cancer and myocardial dysfunction in the short telomere syndromes. Curr. Opin. Genet. Dev. 60, 112–118
36. Manganaro, A.A. and Patria, M.M. (2018) Short telomere syndromes in clinical practice: bridging bench and bedside. Mayo Clin. Proc. 93, 904–916
37. Vieri, M. et al. (2021) Treatment of telomereopathies. Best Pract. Rev. Clin. Haematol. 34, 101–109
38. Agarwal, S. (2018) Evaluation and management of hematopoietic failure in dyskeratosis congenita. Hematol. Oncol. Clin. North Am. 32, 669–685
39. Al-Rahawan, M.M. et al. (2006) Intermittent immune-suppression therapy for aplastic anemia associated with dyskeratosis congenita. Int. J. Hematol. 83, 275–276
40. Trautmann, K. et al. (2012) Eltrombopag fails to improve severe thrombocytopenia in late-stage dyskeratosis congenita and Diamond-Blackfan anemia. Thromb. Haemost. 108, 397–398
41. Townsley, D.M. et al. (2016) Danazol treatment for telomere diseases. N. Engl. J. Med. 375, 1096–1096
42. Khincha, P.P. et al. (2018) Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Adv. 2, 1243–1249
43. MacNeil, D.E. et al. (2015) Telomerase regulation from beginning to end. Genes (Basel) 7, 64
44. MacNeil, D.E. et al. (2019) N-terminal residues of human dyskerin are required for interactions with telomerase RNA that prevent RNA degradation. Nucleic Acids Res. 47, 5368–5380
45. Tseng, C.K. et al. (2015) Poly(A)-specific ribonuclease (PARN) mediates 3'-end maturation of the telomerase RNA component. Nat. Genet. 47, 1482–1488
46. Tseng, C.K. et al. (2018) The hCAGE complex directs alternative 3’-end processing by hRRP2 and PARN. Nat. Commun. 9, 5430
47. Tseng, C.K. et al. (2015) Human telomerase RNA processing and quality control. Cell Res. 13, 2232–2245
48. Dharam, S. et al. (2013) Bone marrow failure and developmental delay caused by mutations in poly(A)-specific ribonuclease (PARN). J. Med. Genet. 50, 738–748
49. Shariat, B.D. et al. (2015) Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat. Genet. 47, 512–517
50. Tummalari, H. et al. (2015) Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. J. Clin. Invest. 125, 2151–2160
51. Gable, D.L. et al. (2019) ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation. Genes Dev. 33, 1581–1596
52. Boyas, B. et al. (2016) Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. J. Clin. Invest. 126, 3377–3382
53. Fox, W.C. et al. (2019) Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita. Blood 133, 1308–1312
54. Muller, H. et al. (2019) PAPD5/7 are host factors that are required for hepatitis B virus RNA stabilization. Hepatology 69, 1398–1411
61. Mueller, H. et al. (2018) A novel orally available small molecule that inhibits hepatitis B virus expression. J. Hepatol. 68, 412–420
62. Shukla, S. et al. (2020) Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congerita. Blood Adv. 4, 2717–2722
63. Nagpal, N. et al. (2020) Small-molecule PAPD5 inhibitors restore telomerase activity in patient stem cells. Cell Stem Cell 26, 896–909
64. Tang, W. et al. (2012) Telomerase RNA biogenesis involves sequential binding by Sm and Lsm complexes. Nature 484, 260–264
65. Chen, L. et al. (2020) Loss of human TGS1 hypermethylase promotes increased telomerase RNA and telomere elongation. Cell Rep. 30, 1358–1372
66. Buemi, V. et al. (2022) TGS1 mediates 2,2,7-trimethylguanosine capping of the human telomerase RNA to direct telomerase dependent telomere maintenance. Nat. Commun. 13, 2922
67. Galati, A. et al. (2022) The S-adenosylmethionine analog sinefungin inhibits the trimethylguanosine synthase TGS1 to promote telomerase activity and telomere lengthening. FEBS Lett. 596, 42–52
68. Codd, V. et al. (2021) Polygenic basis and biomedical consequences of telomere length variation. Nat. Genet. 53, 1425–1433